Iron out KRAS-driven cancer.

Guang Lei, Boyi Gan

Journal: The Journal of experimental medicine 2022;219(4):e20212166

PMID: 35262627

Free Full Text on PubMed Central View on PubMed

Abstract

How to specifically target oncogenic KRAS-driven cancers while sparing normal tissues remains an unmet need in cancer therapy. In this issue of JEM, Jiang et al. (2022. J. Exp. Med.https://doi.org/10.1084/jem.20210739) leveraged KRAS-induced iron addiction in cancer cells to design a clever drug delivery approach to enable selective inhibition of KRAS signaling in mutant KRAS tumors but not in normal tissues, offering a new strategy for treating this largely incurable disease.

Address: Department of Radiation Oncology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

DOI: 10.1084/jem.20212166